Utility of basophil activation test for predicting the outcome of wheezing in children: a pilot study

BMC Immunology

Jinhong Wu¹  Ruoxu Ji²  Jingyang Li²  Jianhua Zhang²  Haipei Liu²  Li Hua²  Yi Chen²  Quanhua Liu²  Wenwei Zhong²  Dingzhu Fang² 

[1] Department of Pediatrics, Shanghai Children’s Medical Center affiliated to Shanghai Jiao Tong University School of Medicine;Department of Pediatrics, Xinhua hospital affiliated to Shanghai Jiao Tong University School of Medicine;

关键词: Asthma;    Wheezing;    Basophil activation test;    CD63;    Children;   

DOI  :  10.1186/s12865-020-00395-4

来源: DOAJ

【 摘 要 】

Abstract Background No reliable biological marker for the diagnosis of asthma in younger children is currently available. In this study, we analyzed the differences in basophil activation test (BAT) results among children with recurrent wheezing episodes who had different asthma outcomes. Results A prospective cohort study was conducted in children aged under 5 years who visited our pediatric respiratory clinic and ward for wheezing. After enrollment, the participants provided samples for a CD63-based BAT performed using an inhalant allergen mixture as a stimulant. Histories of personal allergic diseases and family allergic diseases were evaluated by using a questionnaire. All participants were followed up for 2 years, and their asthma outcomes were evaluated at the end of the follow-up period. The correlation between the BAT results and asthma outcomes was analyzed. Of the 45 originally enrolled children, 38 completed both the follow-up and a BAT. After stimulation with the inhalant mixture, the CD63 expression on basophils and the rate of positive CD63-based BAT results in children diagnosed with asthma were both significantly higher than those in children who were not diagnosed with asthma (p < 0.05 and p < 0.01, respectively). For the prediction of asthma, the positive predictive value and negative predictive value of CD63-based BAT was 71.8 and 69.2%, respectively. The positive likelihood ratio and negative likelihood ratio of CD63-based BAT were 1.70 and 0.3, respectively. Conclusions Our pilot study indicates that CD63-based BAT has potential clinical value for predicting asthma outcome in young children with wheezing episodes.

【 授权许可】

Unknown